Pipeline
Molecule NameIndication/ Therapeutic AreaStage
nuvisertib (TP-3654)
Myelofibrosis/Oncology
1/2enzomenib (DSP-5336)
Acute leukemia/Oncology
2DSP-0390
Glioblastoma/Oncology
1SMP-3124
Solid tumors/Oncology
1/2DSP-0551
Tremor associated with Parkinson’s disease/CNS
1DSP-2342
To be determined/CNS
1DSP-0378
Progressive Myoclonic Epilepsy, Developmental Epileptic Encephalopathy/CNS
1/2DSP-1083
Parkinson’s disease/CNS, Regenerative Medicine
1/2DSP-3077
Retinitis Pigmentosa/CNS, Regenerative Medicine
1/2fH1/DSP-0546LP
Influenza virus prophylaxis/Other
1| Molecule Name | Investigational Indication | PreclinicalP1P2P3 | Therapeutic Area |
|---|---|---|---|
| nuvisertib (TP-3654) | Myelofibrosis | Oncology | |
| enzomenib (DSP-5336) | Acute leukemia | Oncology | |
| DSP-0390 | Glioblastoma | Oncology | |
| SMP-3124 | Solid tumors | Oncology | |
| DSP-0551 | Tremor associated with Parkinson’s disease | CNS | |
| DSP-2342 | To be determined | CNS | |
| DSP-0378 | Progressive Myoclonic Epilepsy, Developmental Epileptic Encephalopathy | CNS | |
| DSP-1083 | Parkinson’s disease | CNS, Regenerative Medicine | |
| DSP-3077 | Retinitis Pigmentosa | CNS, Regenerative Medicine | |
| fH1/DSP-0546LP | Influenza virus prophylaxis | Other |
Medical professionals can visit our contact page to email a request for more information about clinical trial participation.
